7 February 2019

In the American Journal of Respiratory and Critical Care Medicine Lindsey te Brake and colleagues described the shortcomings of a moderate increase in rifampicin dosing, the cornerstone TB drug.

Combined with ongoing trials to optimize the dose of rifampicin ≥35 mg/kg, powerful statistical pooled data analyses will help influence future treatment guidelines and improve the lives of millions of patients with tuberculosis worldwide.

Publication
Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
Te Brake LHM, Boeree MJ, Aarnoutse RE.

Lindsey te Brake, Martin Boeree and Rob Aarnoutse are members of theme Infectious diseases and global health.

Related news items


KWF Roadshow 11 November 2019

10 October 2019

In which way(s) can KWF provide optimal support to oncological research and care? How can we maximize impact on our investments? These questions are pivotal in Ambition 2030: the vision that KWF developed in close cooperation with stakeholders in the oncological field.

read more

A personal touch of Frank Wagener

10 October 2019

In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Frank Wagener.

read more

More than 3000 visitors at Open Day RIHS

10 October 2019

On Sunday 6 October RIHS organized an Open Day in the Weekend of Science (“Weekend van de Wetenschap”) with special guest and television presenter Klaas van Kruistum. More than 3000 visitors became a health scientist for one day and discovered how special healthcare research is.

read more

Dorine Swinkels collaborates with winners of the Nobel Prize in Physiology or Medicine

9 October 2019

The Nobel Prize in Physiology or Medicine 2019 was awarded jointly to William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza for their discoveries of how cells sense and adapt to oxygen availability.

read more

Scaling up nanotherapy

7 October 2019

Scaling up and translating nanotherapy from pre-clinical work in small animal models to a clinical application is not trivial. Raphael Duivenvoorden, theme Renal disorders, and colleagues, published their results on translating a new nanoimmunotherapy in the journal Science Translational Medicine.

read more

A personal touch of Lise Ripken

3 October 2019

In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Lise Ripken.

read more